Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Usana Health Sciences (USNA) over the last 15 years, with Q3 2025 value amounting to $21.9 million.

  • Usana Health Sciences' Other Non-Current Liabilities rose 1705.58% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.9 million, marking a year-over-year increase of 1705.58%. This contributed to the annual value of $18.2 million for FY2024, which is 4939.13% up from last year.
  • Latest data reveals that Usana Health Sciences reported Other Non-Current Liabilities of $21.9 million as of Q3 2025, which was up 1705.58% from $22.7 million recorded in Q2 2025.
  • Usana Health Sciences' Other Non-Current Liabilities' 5-year high stood at $22.7 million during Q2 2025, with a 5-year trough of $10.7 million in Q2 2024.
  • Its 5-year average for Other Non-Current Liabilities is $15.8 million, with a median of $14.7 million in 2021.
  • In the last 5 years, Usana Health Sciences' Other Non-Current Liabilities tumbled by 2995.2% in 2024 and then soared by 11272.74% in 2025.
  • Quarter analysis of 5 years shows Usana Health Sciences' Other Non-Current Liabilities stood at $14.1 million in 2021, then grew by 0.78% to $14.2 million in 2022, then fell by 14.22% to $12.2 million in 2023, then surged by 49.39% to $18.2 million in 2024, then grew by 20.61% to $21.9 million in 2025.
  • Its last three reported values are $21.9 million in Q3 2025, $22.7 million for Q2 2025, and $20.5 million during Q1 2025.